Health Care [ 5/12 ] | Biotechnology [ 29/74 ]
NASDAQ | Common Stock
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses.
Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.
In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers.
The company was incorporated in 2015 and is headquartered in Houston, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 11, 24 | -2.85 Decreased by -1.40 K% | -2.44 Decreased by -16.80% |
| Aug 13, 24 | -1.70 Decreased by -750.00% | -2.51 Increased by +32.27% |
| May 10, 24 | -2.02 Decreased by -621.43% | -3.53 Increased by +42.78% |
| Mar 22, 24 | -5.02 Decreased by -2.08 K% | -3.05 Decreased by -64.59% |
| Nov 13, 23 | -0.19 Increased by +36.67% | -0.24 Increased by +20.83% |
| Aug 10, 23 | -0.20 Increased by +16.67% | -0.27 Increased by +25.93% |
| May 10, 23 | -0.28 Decreased by -16.67% | -0.25 Decreased by -12.00% |
| Mar 22, 23 | -0.23 Decreased by -155.56% | -0.30 Increased by +23.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -10.59 M Decreased by -88.84% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.32 M Increased by +27.73% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 406.00 K Increased by +N/A% | -4.97 M Increased by +32.90% | Decreased by -1.22 K% Decreased by N/A% |
| Dec 31, 23 | 406.00 K Increased by +N/A% | -10.27 M Decreased by -82.46% | Decreased by -2.53 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.61 M Increased by +34.61% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -5.98 M Increased by +11.82% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -7.41 M Decreased by -11.22% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -5.63 M Decreased by -99.22% | Decreased by N/A% Decreased by N/A% |